Pittsburgh, PA

Hemophilia Center of Western PA

Von Willebrand Diseases

Hemophilia A

Hemophilia B

Hemorrhage

Menorrhagia

Type 3 Von Willebrand Disease

Postpartum Hemorrhage

Emicizumab

rFIXFc

Tranexamic Acid

VGA039

Margaret Ragni

Baxalta

Bioverativ

Pfizer

Vega Therapeutics

Nicoletta C Machin

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a multi-center, Phase 1a study to assess the safety, tolerability, PK, and PD of VGA039 following single IV or SC dose administration in healthy subjects and Von Willebrand disease patients.

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease

Hemophilia Center of Western PA | Pittsburgh, PA

Site insights

Work at this site?

Active trials

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease

Trial sponsors